PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
10.71%
Net income growth 10-15% – Solid. Seth Klarman would see it as healthy if margins also remain stable.
-1.40%
Negative yoy D&A growth lowers the drag on net earnings. Benjamin Graham would confirm if it is due to fully depreciated assets or a slower expansion cycle.
No Data
No Data available this quarter, please select a different quarter.
-49.10%
Negative yoy SBC growth reduces new equity issuance. Benjamin Graham would verify that enough talent investment remains for growth.
5.95%
Working capital up to 10% yoy – Acceptable. Seth Klarman would check that no major cash flow strain emerges from moderate expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.80%
A negative yoy AP change means the firm is paying down supplier credit. Benjamin Graham would see it as lowering short-term liabilities if revenue is stable.
823.30%
Above 30% yoy – Major jump. Philip Fisher would demand details on these miscellaneous lines to ensure transparency.
59.87%
Above 30% yoy – Major jump. Philip Fisher would investigate whether this is a recurring or truly one-time distortion.
-19.06%
Negative yoy CFO growth indicates a decline in core cash generation. Benjamin Graham would treat it as a serious warning unless cyclical factors explain it.
96.37%
CapEx above 15% yoy – Significant. Philip Fisher would demand strong evidence of high-ROI projects to offset the spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.44%
A negative yoy shift suggests smaller outflows or net inflows if disposals exceed invests. Benjamin Graham would see a short-term FCF benefit unless growth is compromised.
92.69%
Debt repayment growth above 20% yoy – Strong deleveraging. Warren Buffett would see improved balance sheet health unless expansions are starved.
-1494.87%
A negative yoy figure could mean fewer or no new shares or even net buybacks. Benjamin Graham would see it as positive unless expansions need capital that internal cash cannot provide.
No Data
No Data available this quarter, please select a different quarter.